Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial
Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a Phase 2a clinical trial show. “These impressive clinical trial data are indicative of the potential for ABX464’s unique mechanism of action to safely and effectively

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Hello ibd news,
    Back in 1999 started suffering from severe U.C.By Christmas 2013 totally tired of remissions only lasting a few months.My GI prescribed 12 Delzicol and prednisone together as a new treatment.Did not help for long.Then found Digestacure and Jarrow Formula Probiotic.13 months later total remission.Over 3 and a 1/2 years later still in total remission.I helped 10 others with absolute success!What’s really bizarre doctors totally think what I’ve done is irresponsible.My health has never been better at the age of 59.

Leave a Comment

Your email address will not be published. Required fields are marked *